- A securities class action was filed against Hims & Hers Health (HIMS) and certain executives, with a class period of Aug. 4, 2025 to July 29, 2026 and a Nov. 2, 2026 lead plaintiff deadline.
- The class action cites the July 29, 2026 federal complaint filed by the FTC, alongside co-plaintiffs the State of Utah and the County of Los Angeles.
- The FTC complaint alleges Hims shared sensitive health data with third-party advertising platforms, including Meta Platforms and Snap, via tracking pixels and customer list matching.
- The FTC complaint alleges subscription billing violations under ROSCA, including charging consumers for prescriptions immediately after intake forms and hidden cancellation options.
- HIMS shares fell $4.32 (-14.7%) in a single day, erasing over $970 million in market capitalization, after the FTC complaint.
- Separately, HIMS closed up 6% on Oct 15 after a report that HHS submitted an interim access policy for compounded pharmacies to make peptides for White House review.
Quotes
“including the adequacy of its internal controls, and financial ramifications of the alleged misconduct”